<?xml version="1.0" encoding="UTF-8"?>
<p>The first-line drugs recommended for the treatment of HCMV infection are intravenous ganciclovir or orally administered valganciclovir [
 <xref rid="B83-molecules-25-00942" ref-type="bibr">83</xref>]. Although tolerability of ganciclovir and valganciclovir is acceptable, hematological or neurological side effects can occur. Neutropenia, thrombocytopenia and anemia are the main toxic effects that limit therapy with these drugs. Serum creatinine levels may increase during ganciclovir therapy, which requires monitoring of renal function [
 <xref rid="B84-molecules-25-00942" ref-type="bibr">84</xref>]. Encephalopathy is the neurotoxic effect of ganciclovir and valganciclovir [
 <xref rid="B85-molecules-25-00942" ref-type="bibr">85</xref>]. Foscarnet is also a very effective anti-HCMV drug, and cidofovir is a broad-spectrum antiviral with good activity against HCMV. Both drugs cause a high level of nephrotoxicity that limits treatment [
 <xref rid="B83-molecules-25-00942" ref-type="bibr">83</xref>].
</p>
